Core Viewpoint - The article discusses the critical role of fundraising investment projects (募投项目) in corporate development, highlighting the delays and terminations faced by several companies in the industry due to various factors [1][3]. Summary by Company 普源精电 (Puyuan Precision Electric) - The company announced a delay in the "Shanghai R&D Center Construction Project" to April 2026 due to changes in the implementation method and the late completion of the new building [4][5]. 高华科技 (Gaohua Technology) - The "Gaohua R&D Capability Construction Project" has been postponed to June 30, 2026, due to tight operating funds before the IPO and the establishment of two new subsidiaries affecting the project timeline [6]. 莱伯泰科 (Leibotai Technology) - The timeline for the "Trace and Ultra-trace Element Analysis ICP-MS and Online Analysis System Production and R&D Project" has been extended to September 2026, influenced by evolving user demands and market conditions [7][8]. 迈拓股份 (Maituo Co., Ltd.) - The "Ultrasonic Measuring Instrument Production Base Construction Project in Nanjing" is delayed until December 31, 2025, due to delays in obtaining construction permits and other unforeseen factors [9][10]. 智能自控 (Intelligent Control) - The company decided to extend the timeline for its fundraising projects due to changes in the macroeconomic environment and market conditions, affecting project completion [11]. 碧兴物联 (Bixing IoT) - The "Smart Ecological Environment Big Data Service Project" and "Smart Water Big Data Traceability Analysis Service Project" have been postponed to August 2026, with no changes to the project scope or funding [12][13]. 煜邦电力 (Yubang Electric) - The company has terminated certain sub-projects and extended the timeline for remaining projects to December 2026, citing increased competition and market conditions [14][15]. 天罡股份 (Tiangang Co., Ltd.) - The "IoT Smart Ultrasonic Measuring Instrument Industrialization Project" and "R&D Center Upgrade Construction Project" have been postponed to June 30, 2026, due to equipment procurement delays and project adjustments [17][18].

Core Viewpoint - Beijing Labtech Instrument Co., Ltd. is holding a half-year performance briefing on September 24, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in Q&A sessions [2][3]. Group 1: Meeting Details - The performance briefing is scheduled for September 24, 2025, from 16:00 to 17:00 [6]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible online [2][6]. - The format of the meeting will be an interactive online session, enabling real-time communication with investors [3][5]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date [5]. - A pre-collection of questions will be available from September 17 to September 23, 2025, allowing investors to submit inquiries via the website or email [5][6]. - The company will address commonly asked questions during the briefing [3][5]. Group 3: Attendees - Key attendees include Mr. Hu Ke, Chairman and General Manager, Ms. Yu Hao, Secretary of the Board and Financial Officer, and Ms. Yin Bitiao, Independent Director [4].

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-035 北京莱伯泰科仪器股份有限公司 关于召开 2025 年半年度业绩说明会的公告 投资者可于 2025 年 09 月 17 日 （星期三） 至 09 月 23 日 （星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqtzb@labtechgroup.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 北京莱伯泰科仪器股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 09 月 24 日（星期三） 16:00-17:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：202 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-034 北京莱伯泰科仪器股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 09 月 15 日 （二） 股东会召开的地点：北京市顺义区空港工业区 B 区安庆大街 6 号北京莱 伯泰科仪器股份有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 28 | | --- | --- | | 普通股股东人数 | 28 | | 2、出席会议的股东所持有的表决权数量 | 41,151,918 | | 普通股股东所持有表决权数量 | 41,151,918 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 61.6247 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于北京莱伯泰科仪器股份有限公司 2025 年第一次临时股东会的法律意见书 致：北京莱伯泰科仪器股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）以及中国证券监督管理委员会颁布的 《上市公司股东会规则（2025修订）》（以下简称"《股东会规则》"）的规定， 北京市竞天公诚律师事务所（以下简称"本所"）指派律师对公司2025年第一次临 时股东会（以下简称"本次股东会"）进行现场见证，并就本次股东会的有关事宜 出具本法律意见书。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见书所认定的事实真实、准确、 完整，所发表的结论性意见合法、准确 ...

Summary of the Conference Call on the Scientific Instrument Industry Industry Overview - The scientific instrument industry in China is experiencing growth driven by increasing R&D expenditure, which reached 3.34 trillion yuan in 2023, a year-on-year increase of 8.4% [1][3] - The market for scientific instruments, including mass spectrometry, chromatography, and spectroscopy, exceeds 50 billion yuan, but remains highly dependent on imports, with mass spectrometry and chromatography import rates at 90% and 88% respectively [1][3] Key Insights - The proportion of R&D expenditure to GDP in China has been steadily increasing, reaching 2.6% in 2023, indicating stronger governmental support for technological innovation and a rising demand for high-end scientific instruments [1][3][6] - The mass spectrometry market in China is approaching 20 billion yuan, with a growth rate of approximately 15%, but it is still heavily reliant on imports, particularly from the U.S., which maintains a stable market share of around 20% [1][8][10] - The scientific service industry encompasses research institutions, universities, and innovative enterprises, providing high-tech solutions and third-party testing services, characterized by high technological content and talent concentration [4][5] Market Dynamics - The scientific instrument supply chain consists of three main segments: 1. Reagent and consumables companies (e.g., Titan Technology, Aladdin) 2. Scientific instrument manufacturers (e.g., Focused Photonics, Labtech) 3. Third-party testing service providers (e.g., Huace Testing, Puni Testing) [6] - The increasing focus on domestic scientific instruments due to U.S.-China trade tensions is expected to enhance the market share of domestic manufacturers [3][10] Competitive Landscape - There is a significant gap between Chinese scientific service companies and their overseas counterparts, with leading foreign firms like Merck and Agilent having market capitalizations exceeding 100 billion USD, while only five Chinese companies exceed 10 billion USD in market cap [2][11] - The average gross margin for Chinese companies is 46%, lower than the 52% average for foreign companies, indicating potential for profit margin improvement as domestic companies scale up [11][12] Future Outlook - As penetration rates increase and costs decrease, the gross margins of Chinese scientific service companies are expected to improve, potentially leading to the emergence of new domestic leaders in the industry [12] - Investment recommendations include focusing on companies engaged in R&D and the scientific instrument sector, such as Focused Photonics, Wuyi Technology, and Labtech, which are in the early stages but show significant growth potential [13]

Core Viewpoint - The company is preparing for its first extraordinary general meeting of shareholders in 2025, focusing on maintaining order and protecting the rights of shareholders during the meeting [1][2]. Meeting Procedures - The meeting will take place on September 15, 2025, at 14:00 in the company's conference room located in Beijing [5]. - Attendees must arrive 30 minutes early to complete registration and verify their identity [1][2]. - The meeting will follow a specific agenda, including the election of vote counters and the discussion of three key proposals [5][6]. Voting and Participation - Shareholders and their proxies have the right to speak, inquire, and vote during the meeting [2][3]. - Voting will be conducted through both on-site and online methods, with specific time slots allocated for online voting [5][3]. - The company will utilize a reminder service to ensure that small and medium investors are informed about the meeting and can participate [3][4]. Proposals for Discussion - Proposal 1: Reappointment of the accounting firm Xinyong Zhonghe for the 2025 audit, based on their professional competence and independence [6]. - Proposal 2: Revision of the company's internal management system to enhance governance and operational standards [6][7]. - Proposal 3: Establishment of a compensation management system for directors and senior management, in compliance with relevant laws and regulations [7].

证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 2025 年第一次临时股东会 会议资料 2025 年 9 月 北京莱伯泰科仪器股份有限公司 2025年第一次临时股东会会议资料 2025 年第一次临时股东会会议资料 目录 | 2025 年第一次临时股东会会议须知 2 | | --- | | 年第一次临时股东会会议议程 2025 4 | | 议案一：关于公司续聘会计师事务所的议案 6 | | 议案二：关于修订公司内部管理制度的议案 7 | | 议案三：关于制订《北京莱伯泰科仪器股份有限公司董事、高级管理人员薪酬 | | 管理制度》的议案 8 | 1 北京莱伯泰科仪器股份有限公司 2025年第一次临时股东会会议资料 2025 年第一次临时股东会会议须知 为了维护北京莱伯泰科仪器股份有限公司（以下简称"公司"）全体股东的 合法权益，确保股东会的正常秩序和议事效率，保证股东会的顺利进行，根据《中 华人民共和国公司法》、《中华人民共和国证券法》、《上市公司股东会规则》以及 《北京莱伯泰科仪器股份有限公司章程》、《北京莱伯泰科仪器股份有限公司股东 会议事规则》等相关规定，特制定 2025 年第一次 ...

Core Viewpoint - The recent financial report of Laibotai Technology (688056) indicates a decline in revenue and net profit for the first half of 2025 compared to the previous year, raising concerns about the company's financial health and operational efficiency [1][3]. Financial Performance - Total revenue for the first half of 2025 was 192 million yuan, a decrease of 10.33% year-on-year [1]. - Net profit attributable to shareholders was 21.09 million yuan, down 11.53% year-on-year [1]. - In Q2 2025, total revenue was 92.91 million yuan, reflecting a 14.45% decline year-on-year, while net profit for the quarter was 8.33 million yuan, a significant drop of 32.12% [1]. - The gross profit margin improved slightly to 45.55%, an increase of 1.92% year-on-year, while the net profit margin decreased to 10.99%, down 1.33% year-on-year [1]. - Total operating expenses (sales, management, and financial expenses) amounted to 42.90 million yuan, representing 22.35% of revenue, an increase of 3.4% year-on-year [1]. Asset and Liability Management - Accounts receivable reached a significant level, with accounts receivable to net profit ratio at 142.89%, indicating potential liquidity issues [1][3]. - Cash and cash equivalents decreased to 266 million yuan, down 16.97% year-on-year [1]. - Interest-bearing liabilities increased by 36.18% to 1.01 million yuan [1]. Earnings and Cash Flow - Earnings per share (EPS) decreased to 0.32 yuan, down 8.57% year-on-year [1]. - Operating cash flow per share was -0.12 yuan, a drastic decline of 89.31% year-on-year [1]. - The company’s return on invested capital (ROIC) was reported at 4.07%, indicating weak capital returns compared to historical averages [3]. Business Model and Strategy - The company relies heavily on research and marketing for its performance, necessitating a deeper analysis of these driving factors [3]. - The company has focused on differentiated competition and collaboration, particularly in sample pretreatment equipment, before venturing into mass spectrometry development in 2019 [4].

Meeting Information - The shareholder meeting is scheduled for September 15, 2025, at 14:00 [1] - The meeting will be held at the company's conference room located at No. 6 Anqing Street, Zone B, Airport Industrial Area, Shunyi District, Beijing [1] - Voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - The online voting period is from September 15, 2025, during trading hours: 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders can vote via the trading system or the internet voting platform [4] - The company will provide a reminder service for small and medium investors to ensure participation [4] Agenda Items - The meeting will review three non-cumulative voting proposals: 1. Fund management measures 2. Major operational and investment decision management system 3. Compensation management system for directors and senior management [2][3] - These proposals were approved by the company's fifth board of directors during its third meeting [2] Attendance and Registration - Shareholders registered with China Securities Depository and Clearing Corporation Limited as of the close of trading on September 8, 2025, are eligible to attend [5] - Shareholders can appoint proxies to attend and vote on their behalf [6] - Registration must be completed by September 11, 2025, for non-attending shareholders [6] Additional Information - The company will not cover travel and accommodation expenses for attendees [8] - Attendees are advised to arrive at least 30 minutes early for registration [8]